AVANIR Pharmaceuticals to Present at Annual Trade Visions Conference
Dr. Fernandez's presentation will focus on AVANIR's opportunities, challenges and options in venturing into the Korean pharmaceutical market. Dr. Fernandez will share the Company's experiences in establishing a successful relationship with Boryung Pharmaceuticals, AVANIR's Korean licensing partner for docosanol 10% cream, a topical cold sore medication. In addition, this panel will feature Sang-jung Nam, Consul for Economic Affairs, Korean Consulate General who will address the "Economic and Business Climate in Korea."
AVANIR received marketing approval in Korea last month for docosanol 10% cream, sold in the U.S. as Abreva(TM). Boryung Pharmaceuticals, a Korean drug company, will market docosanol 10% cream in Korea under an exclusive license agreement that provides royalties to AVANIR. Boryung was successful in obtaining non-prescription status, and is scheduled to begin marketing the product under the trade name "Herepair" at the end of this month.
AVANIR Pharmaceuticals, based in San Diego, is a biopharmaceutical drug discovery and development company with an FDA-approved product. AVANIR is engaged in research, discovery, development and licensing of innovative drug products and, through its subsidiary Xenerex Biosciences, antibody generation services. The Company's website is http://www.avanir.com .
The information contained in this press release, including any forward- looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words as "estimate," "anticipate," "intend," "plan" or "expect". Preliminary research findings are not always supportable by the scale-up of commercial operations, and many known and unknown risks and uncertainties could cause actual results to differ materially from those indicated in these forward-looking statements. The Company can give no assurance that product launch in Korea will be timely for docosanol 10% cream. Further, market acceptance for docosanol and other drug products is unpredictable and substantially outside of the influence and/or control of the Company.
For further information please contact: Gregg Sloate, General Information, +1-310-407-6547, firstname.lastname@example.org, or Tricia Ross, Analyst/Investor, +1-310-407-6540, email@example.com, or Tim Grace, Media, +1-312-640-6667, firstname.lastname@example.org, all of FRB|Weber Shandwick, for AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations, AVANIR Pharmaceuticals, +1-858-622-5202, email@example.com
SOURCE AVANIR Pharmaceuticals
Gregg Sloate, General Information, +1-310-407-6547,
firstname.lastname@example.org, or Tricia Ross, Analyst/Investor, +1-310-407-6540,
email@example.com, or Tim Grace, Media, +1-312-640-6667,
firstname.lastname@example.org, all of FRB|Weber Shandwick, for AVANIR
Pharmaceuticals; or Patrice Saxon, Investor Relations, AVANIR Pharmaceuticals,
/Company News On-Call: http://www.prnewswire.com/comp/509050.html
Copyright (C) 2002 PR Newswire. All rights reserved.